TEVA-FROVATRIPTAN 2.5 MG — DIN 02415844
FROVATRIPTAN (FROVATRIPTAN SUCCINATE) : 2.5 MG · ENDO OPERATIONS LTD. · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is TEVA-FROVATRIPTAN?
TEVA-FROVATRIPTAN 2.5 MG contains FROVATRIPTAN (FROVATRIPTAN SUCCINATE) : 2.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02415844, held by ENDO OPERATIONS LTD., supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 10-Jul-2026. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is TEVA-FROVATRIPTAN used for?
TEVA-FROVATRIPTAN (frovatriptan tablets) is indicated for the acute treatment of migraine attacks with or without aura in adults. It is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic, ophthalmoplegic or basilar migraine.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Frovatriptan cost around the world?
Frovatriptan is listed on 3 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Italy publishes a prezzo al pubblico (classe A); Romania publishes a max producer price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| Italy | prezzo al pubblico (classe A) | 5 | 8 |
| Austria | KVP (Kassenverkaufspreis) | 2 | 4 |
| Romania | max producer price | 1 | 1 |
13 pack listings across 8 brand entries and 3 price bases, refreshed 03 Sep 2026. Ranges span every Frovatriptan pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Frovatriptan in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
5 holders have a Canadian DIN containing Frovatriptan, across 6 DINs, of which 5 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ENDO OPERATIONS LTD. | 2 | 1 | FROVA, TEVA-FROVATRIPTAN | Sourceable in Canada |
| APOTEX INC | 1 | 1 | APO-FROVATRIPTAN | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 1 | 1 | JAMP FROVATRIPTAN | Sourceable in Canada |
| MINT PHARMACEUTICALS INC | 1 | 1 | MINT-FROVATRIPTAN | Sourceable in Canada |
| SANIS HEALTH INC | 1 | 1 | FROVATRIPTAN | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 2.5 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | blister cards of 7 tablets, 1 blister card per carton |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Frovatriptan |
|---|---|
| ATC code | N02CC07 |
| AHFS class | 28:32.28 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02415844 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2415844 |
| Brand name | TEVA-FROVATRIPTAN |
| Generic / active ingredient | FROVATRIPTAN (FROVATRIPTAN SUCCINATE) : 2.5 MG |
| Market authorization holder | ENDO OPERATIONS LTD. |
| Health Canada schedule | Prescription |
| ATC code | N02CC07 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N02CC |
| Current status | CANCELLED POST MARKET |
| Status date | 10-Jul-2026 |
| Original market date | 2015-01-16 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
5 of 6 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-FROVATRIPTAN | 2.5 MG | TABLET | APOTEX INC | MARKETED | 02426471 |
| FROVA | 2.5 MG | TABLET | ENDO OPERATIONS LTD. | MARKETED | 02257084 |
| FROVATRIPTAN | 2.5 MG | TABLET | SANIS HEALTH INC | MARKETED | 02535475 |
| JAMP FROVATRIPTAN | 2.5 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02497131 |
| MINT-FROVATRIPTAN | 2.5 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | 02509687 |
2 · Same class — other molecules in ATC N02CC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Rizatriptan | ACCEL-RIZATRIPTAN ODT · ACT RIZATRIPTAN · ACT RIZATRIPTAN ODT · AG-RIZATRIPTAN ODT · +36 more | 85 | 34 | Yes |
| Sumatriptan | ACT SUMATRIPTAN · AG-SUMATRIPTAN · APO-SUMATRIPTAN · AVA-SUMATRIPTAN · +27 more | 80 | 32 | Yes |
| Eletriptan | APO-ELETRIPTAN · APO-ELETRIPTAN TABLETS · AURO-ELETRIPTAN · ELETRIPTAN · +6 more | 20 | 16 | Yes |
| Zolmitriptan | AG-ZOLMITRIPTAN ODT · APO-ZOLMITRIPTAN · APO-ZOLMITRIPTAN RAPID · AURO-ZOLMITRIPTAN · +33 more | 45 | 15 | Yes |
| Almotriptan | ALMOTRIPTAN · APO-ALMOTRIPTAN · AXERT 12.5MG · AXERT 6.25MG · +5 more | 13 | 6 | Yes |
| Frovatriptan | APO-FROVATRIPTAN · FROVA · FROVATRIPTAN · JAMP FROVATRIPTAN · +2 more | 6 | 5 | Yes |
| Naratriptan | AMERGE · APO-NARATRIPTAN · SANDOZ NARATRIPTAN · TEVA-NARATRIPTAN | 7 | 3 | Yes |
| Sumatriptan And Naproxen | SUVEXX | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N02C
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N02CD | Atogepant · Eptinezumab · Erenumab · Fremanezumab · Galcanezumab · +2 more | 17 | 15 |
| N02CA | Dihydroergotamine · Ergotamine · Ergotamine, Combinations Excl. Psycholeptics · Ergotamine, Combinations With Psycholeptics · Methysergide | 15 | 2 |
| N02CX | Clonidine · Pizotifen | 3 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.